Vesnarinone: a differentiation-inducing anti-cancer drug.
Vesnarinone has been shown to be a unique anti-proliferating, differentiation-inducing and apoptosis inducing drug against several human malignancies, including leukemia and several solid tumors. Furthermore, vesnarinone potentiates the effect of conventional cytotoxic chemotherapy or radiation therapy. Combination of differentiation-inducing therapy by vesnarinone with conventional chemotherapy or radiation therapy might be second- or third-line therapy in patients with advanced cancer. Analysis of the molecular mechanisms of the tumor differentiation therapy by vesnarinone might provide selective and targeted molecules for novel tumor dormancy therapy.
Kawamata
Hitoshi
H
Department of Surgical and Molecular Pathology, Dokkyo University School of Medicine, Mibu, Tochigi, Japan. h-kawama@dokkyomed.ac.jp
Omotehara
Fumie
F
Nakashiro
Koh-ichi
K
Uchida
Daisuke
D
Hino
Satoshi
S
Fujimori
Takahiro
T
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011719:Pyrazines; D011804:Quinolines / Q000737:chemistry / Q000627:therapeutic use*; D012097:Repressor Proteins / Q000235:genetics / Q000302:isolation & purification
D000970:Antineoplastic Agents; D011719:Pyrazines; D011804:Quinolines; D012097:Repressor Proteins; C099726:TSC22D1 protein, human; C490983:Tgfb1i4 protein, mouse; C041667:vesnarinone